<DOC>
	<DOCNO>NCT00320879</DOCNO>
	<brief_summary>Aim : To evaluate renoprotective effect reflect short-term change albuminuria ultra high dos irbesartan Type 2 diabetic patient microalbuminuria Design : A double-masked randomized cross-over trial include 60 hypertensive Type 2 diabetic patient microalbuminuria ongoing antihypertensive medication . At inclusion , previous antihypertensive treatment discontinue replace bendroflumethiazide 5 mg o.d . entire study . Following two month wash-out ( baseline ) , patient treat randomly irbesartan 300 , 600 900 mg o.d. , dose two month . End-points evaluate end study period include urinary albumin excretion rate ( UAE , mean three 24-hrs collection ) , 24-hrs blood pressure ( ABP ) ; GFR ( 51Cr-EDTA ) .</brief_summary>
	<brief_title>Optimal Dose Irbesartan Renoprotection Type 2 Diabetic Patients With Persistent Microalbuminuria</brief_title>
	<detailed_description>Aim : The primary aim study evaluate antiproteinuric effect irbesartan 300 , 600 900 mg daily type 2 diabetic patient microalbuminuria . Secondary evaluate effect 24-h ambulatory blood pressure , glomerular filtration rate ( GFR ) , urinary TGF beta excretion , marker endothelial dysfunction , finally evaluate association treatment response genotypes possible implication risk cardiovascular disease . Patients 60 type 2 diabetic patient persistent microalbuminuria ( least two three 24-h urinary collection albumin excretion 30 300 mg/24-h ) . Duration study 38 week ( 8 week wash-out 30 week double-blind randomized cross-over ( treatment irbesartan 300 , 600 900 mg 10 week dose level ) ) . Design The study consist eight week wash-out period follow double-blind randomize three 10 week treatment period cross-over trial ( please see enclosed flow chart ) . Wash-out period : Eight week prior randomization previous antihypertensive medication discontinue replace hydrochlorothiazide 25 mg daily throughout entire study period . Hydrochlorothiazide add reduce blood pressure elevation edema formation trial eliminate influence vary dietary salt intake effect irbesartan double blind treatment period . Double-blind cross-over period : All patient receive treatment irbesartan 300 , 600 900 mg daily random order , without wash-out treatment period . All treatment period 10 week duration . They consist initial two week titration period irbesartan 300 mg o.d . minimize risk adverse event include hypotension cross-over dos follow eight week period full dose give treatment level . For safety reason blood pressure , serum potassium serum creatinine measure 4 week begin treatment period ( two week full dose treatment period reach ) . End-points evaluate wash-out period ( baseline ) end treatment period . Methods Albuminuria assess turbidimetry three 24-h urinary sample . 24-h ambulatory blood pressure Takeda TM-2420/2421 device . GFR plasma clearance 51Cr-EDTA . DNA extract venous sample determine genotype possible implication risk cardiovascular disease . Initially evaluate influence ACE/ID- , Angiotensin II type I receptor ( A1166C ) - angiotensinogen ( M235T ) polymorphism . Endpoints Primary endpoint : change albuminuria Secondary endpoint : 24-h ambulatory blood pressure , glomerular filtration rate ( GFR ) , evaluate association treatment response genotypes possible implication risk cardiovascular disease</detailed_description>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Type 2 diabetes ( WHO criteria ) age 18 year . Persistent microalbuminuria ( urinary albumin excretion 30 300 mg/24h least two three 24urinary collection Systolic blood pressure &gt; 110 mmHg Serum creatinine &gt; 150 micromol/l Known nondiabetic renal disease Pregnancy fertile woman use adequate contraception ( intrauterine device , sterilization oral anticonception ) Systolic blood pressure persistently &gt; 180 mm Hg &lt; 100 mm Hg Diastolic blood pressure persistently &gt; 105 mm Hg Plasma potassium &gt; 4.8 mmol/l Heart failure , acute myocardial infarction , unstable angina coronary bypass surgery within previous three month . Known intolerance angiotensin II receptor blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>diabetes</keyword>
	<keyword>microalbuminuria</keyword>
	<keyword>angiotensin II receptor blockade</keyword>
	<keyword>irbesartan</keyword>
	<keyword>dose-response</keyword>
	<keyword>randomize</keyword>
	<keyword>double-blind</keyword>
	<keyword>renin-angiotensin-aldosterone system</keyword>
	<keyword>clinical</keyword>
	<keyword>hypertension</keyword>
</DOC>